Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
---|
CEO | Mr. Christoffer Rosenblad |
IPO Date | Oct. 8, 2012 |
Location | Sweden |
Headquarters | MAessans gata 10 |
Employees | 161 |
Sector | Healthcare |
Industries |
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Past 5 years
USD 18.98
USD 30.29
USD 19.80
USD 3.11
USD 19.20
StockViz Staff
February 4, 2025
Any question? Send us an email